Amendment: Medical devices with human blood/plasma derivatives (Directive 93/42/EEC)

This procedure concerns amendments to existing rules for medical devices that use stable derivatives from human blood or plasma. It aims to ensure these products meet high safety and quality standards.

The changes will affect manufacturers of these specific medical devices and potentially healthcare providers. Consumers will benefit from enhanced safety assurances for products derived from human blood or plasma.